This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cardiac Myosin Activation With Omecamtiv Mecarbil in Systolic Heart Failure
A latge RCT of the first myosin inhibitor in severe chronic heart failure: somewhat difficult to interpret results, as deaths were slightly higher in the intervention group while there was no 'significant' benefit in cardiovascular deaths. The authors discuss the possibility of benefit in lower ejection fractions and proceed to discuss and present subgroups in an effort to glean some granularity in indications for omecamtiv mecarbil.